Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Cinclus Pharma, Audiocast, Q2'26

By Inderes8/19/2026, 8:00 AM
Cinclus Pharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Christer Ahlberg
00:00 - 15:49

Thank you. And hi everyone, and welcome to Cinclus Pharma's second quarter 2026 earnings call. I am Christer Ahlberg and I'm CEO of Cinclus Pharma. And with me here today, I also have our CFO, Magnus Christensen. And we will walk you through the key developments from the second quarter, after which we will be happy to answer any questions you may have. Our lead asset, linaprazan glurate, is the next-generation PCAB, and that substance offers sustained around-the-clock acid control that distinguishes it from the current standard of care with proton pump inhibitors, the PPIs, and all other PCABs available on the market or in development, specifically for severe erosive GERD. The patient population we are addressing is large and underserved. Roughly 10 million people across the US and Europe live with severe erosive GERD, and a substantial share of them are not adequately healed or treated by today's standard of care. This makes this a specialty-driven commercial opportunity rather than a primary care one. Better healing and better symptom control translate directly into clinical and commercial differentiation. And that's our goal. Our Phase III program, HEEALING1, began in September 2025, and I am very pleased to report that it has completed enrollment; in early July, we announced that we had exceeded the protocol-specified target number of patients. That was very good news for us. HEEALING1 topline results are expected in the fourth quarter of this year, as previously communicated, which could represent a major value inflection point for the company. Our program is de-risked at this stage. We have a robust clinical data package, alignment with both the US FDA and the European EMA regarding our regulatory strategy, and we have a well-defined CMC plan that we have already communicated before. Linaprazan glurate has, in 2026, been launched in China as planned through our Sinorda licensing agreement and also through their partner Huadong, which is the second-biggest pharma company in China. We are also restricted from giving any details about the launch at this stage. But of course it looks very promising, and we are progressing very well during the launch in China. And we are, of course, excited that we have seen the first commercial launch of linaprazan glurate globally. And it is, of course, a very important validation of the drug. We see that the first-generation PCABs are rapidly gaining traction. PCABs are now available in more than 30 countries globally, and local treatment guidelines are increasingly adopting recommendations. And that is, of course, very good for us. There is no doubt that PCABs are about to take over the market from the current standard treatment with proton pump inhibitors like Losec and Nexium and other products in that group. Regarding the enrollment completion of the Phase III study, we are very pleased with the execution of the first Phase III study, HEEALING1, which has developed according to our plans since the start last fall. We announced in early July that our enrollment in the study was completed, and at that time, we had randomized 521 patients, exceeding our protocol-specified target of 501 patients. The total number of patients in the study now is actually 523, and the study is being conducted across eight European countries. The primary endpoint is superiority to lansoprazole. That is a unique primary endpoint. And we are going to deliver it in the healing of severe erosive GERD patients, specifically LA grade C and D, and we are going to deliver on that. After four weeks of treatment. Key secondary endpoints cover healing. Of course, it covers symptom relief through four weeks, but also through eight weeks. For both LA grade C and D patients. But also, of course, all patients. So all grades as well. A, B, C and D. And the study will be followed by our second and final Phase III study, HEEALING2. That will also evaluate maintenance therapy and will be done at clinical sites in both Europe and the US as well. HEEALING2 is planned to initiate following HEEALING1 topline results. This slide highlights our HEEALING1 progress. We screened the last patient in June and reached our enrollment target, having randomized the last patients in July. The remaining milestones are outlined below. The topline results for the last patient treated are expected within a few weeks, and the last patient's last visit is expected in September or October this fall, which will conclude the clinical phase. Thereafter, the remaining steps will be data cleaning and database lock. And finally, the readout that we expect during the fourth quarter of the year. We have good visibility over the remaining timeline of the study. This slide you have seen before, but it is very important. It shows how well a drug controls gastric acid over a 24-hour day. It predicts how well it heals the erosive GERD patients. The relationship is linear, as you can see. Whether you look at PPIs or PCABs? That is the central scientific argument for the linear dose-response at this stage, as acid control is the biomarker that drives healing in this disease, and the more of the day, the 24 hours you can keep gastric pH above four, the better. The better it is for the patients. And that is precisely the variable under which linaprazan glurate is differentiated. But that has also been our aim and objective since we began developing the product. This slide illustrates the number of hours the pH in the stomach is below pH 4 for different treatments. Given the treatment alternatives available in the market. Over the. Over the study period. Over the decades and the history of the development of these kinds of drugs with the old H2 blockers, you can see to the left, such as Zantac, that were launched during the. In the 70s, pH was below four during 16 hours per day, but still, it was a dramatic improvement compared to having nothing. And this drug became the most sold drug in the world and actually built Glaxo into the big pharma company it is today, looking into the development of the next step for the proton pump inhibitor that came to the market in the end of the 80s and the beginning of the 90s. Here you can see a reduction between 7 to 14 hours with PPIs. Below pH four and that, as you know, these drugs Losec, Prilosec, and Nexium became the most sold drugs in the world at the same time, and that actually built Astra and AstraZeneca into what they are today. So these drugs are important for companies. And when they are developing the company, and also when we see now the next step in this evolution, you see that the first generation of PCABs were launched in 2015 and now in 2024 in the US, where you can see that you have another dramatic step downwards in hours of pH below four. Actually, what they managed to do in Japan, where it was launched first, was to become the most sold drug in Japan. And with close to 1 billion USD in sales only there. So, of course, acid control improvement matters to actually build the market and to build companies launching these kinds of products. And what you can see now is that our studies show that linaprazan glurate has a unique ability to maintain pH below four for only one hour per day. This is a major improvement to all existing treatment alternatives on the market and in development, highlighting a significant market potential as you understand. This is really the end of the treatment ladder. You can say that now you have reached the goal that also can help the severely ill patients. And also, if you remember the slide I showed you before with the biomarker relating the linear correlation between acid control and the healing of these patients. We also wanted to control this and double-check if it works also for PCAB. And the last study that has been performed, the Phase III trials being performed in the US and Europe with Vonoprazan. Tegoprazan. They have used the same comparator of the PPI, Lansoprazole. And if we start from the beginning here with the acid control of each of these drugs. Lansoprazole is actually interesting to see when you plot these results into the curve that we showed you before. The biomarker curve is spot on. It is perfectly spot on. Related also to this curve. So if you actually look at the acid control, Lansoprazole is 63% after eight weeks. And in the results of the clinical studies of the Phase III clinical studies of Tegoprazan and Vonoprazan in the US and Europe, they came to a conclusion of 68% to 72%. That is perfectly on the line. Which is perfectly on the biomarker line I showed you before going further into Tegoprazan, which has an acid control of 75%. And actually, their clinical data showed 83% healing in the Phase III trial after eight weeks for LA grade C/D patients. And if you just compare 75% into this curve, you see it is perfectly on the line of 80% plus in healing. Looking into vonoprazan, they have a slightly higher control rate of up to 85%. And if you look at their clinical data from the phase three, they reached 91.7% healing of the C and D patients after eight weeks. It is also perfectly spot on the curve. So you can really predict outcomes with this data and this curve. And therefore it is very interesting to see that we have 96%. It will be very interesting to follow our healing rates after eight weeks for the LA grade C and D patients coming to the end of the year, when we know the results from our Phase III study. But of course, our ambition is to have in absolute figures also the best healing rates for the C and D patients, but not only the best healing rates. We also look forward to demonstrating the benefits of our unique acid control. We also want to have the biggest effect difference compared to the PPIs. The biggest delta. As we call it, in our phase two trial, we delivered a 55% delta in absolute percentage figures, 93% versus 38% for the PPIs, which is 55 percentage points in difference. If you look into the other PCABs, they have delivered something between 15% to 20% delta compared to the same comparator, lansoprazole, after two and eight weeks. And of course, we want to have the best healing rates, but we also want to deliver the best delta, the effect difference between ourselves and the PPI that we are comparing with. That is the same as what Vonoprazan and Tegoprazan have done. So we will have a uniqueness in reaching the best-in-class positioning here. On top of that, we also want to deliver superiority in symptom relief versus the PPI, both in daytime and nighttime symptoms. And if we can do that, which we have good chances to do, this could definitely be a game changer and a unique position. Best-in-class position that no one has delivered before. And that is, of course, something that we have aimed for. And that is of course done thanks to the uniqueness of our acid control. That was the aim from the beginning when we developed this product, that we should have total acid control, which could also have a chance to help the most severe patients. Okay, I think I will stop there, and then we can move into some financials. And I hand over then to you, Magnus.

Magnus Christensen
15:51 - 19:06

Thank you. Christer. Turning to our second quarter results, we ended the quarter with a cash balance of 388 million SEK, which includes the structured financing agreement drawn under the facility in the first quarter of this year. The cash flow in the quarter amounts to -88 million SEK, which reflects the continued focus and investment on HEEALING1 execution and its upcoming milestones. The R&D expenses remain the clear driver of our cost base at 89% of operating expenses in the second quarter, compared with the average of 87% over the prior four quarters. Looking at the year-over-year comparison for Q2, revenue was approximately 2 million SEK, and it consists primarily of the license income from the Zentiva partnership for the commercialization of linaprazan glurate in Europe; the revenue from the Zentiva deal, which includes an upfront payment of €30 million in Q2 2025, is being amortized across the Phase III studies. Operating expenses were 96 million SEKm, driven by the ongoing Phase III study activity. EBIT was -95 million SEK, reflecting the higher R&D expenses associated with the full Phase III execution. And if you look at the financial net line, we recorded 16.3 million SEK. This consists mainly of the revaluation of the structured financing of the facility, as well as interest to the bank and the interest payments to the facility. The net loss for the quarter was almost 79 million SEK, driven by the higher R&D expenses from the ongoing Phase III study. And if we look at the balance sheet, non-current assets have increased, and that primarily reflects the leasing liabilities for the new office premises. Other current assets decreased mainly due to prepayments to the CRO. And that is in line with the contract that we have. Cash decreased by 200 million SEK. And with the 86 million SEK structured financing drawdown partially offsetting the increased R&D expenses as the Phase III activity ramped to full execution, non-current liabilities decreased by almost 30 million, mainly representing the contract liability from the Zentiva deal, which is amortized. Beyond one year, non-current liabilities decreased, and current liabilities increased by 100 SEKm, primarily driven by the structured financing, debt convertibles, and warrants, plus a short-term contract liability from the Zentiva deal. And with this, I'll hand back over to Christer.

Christer Ahlberg
19:08 - 19:52

Okay. Thank you. Thank you for these figures. And that brings us to the end of our formal remarks before we open the line for questions. A few important dates lie ahead. The Q3 results will be reported on November 11th this year, and the Q4 results will be reported on February 17th next year. 2027. And of course, we look forward to keeping you updated on the remaining steps of the HEEALING1 study and results of the fourth quarter of this year. The defining clinical milestones lie ahead for the company. And with that, I would like to open the line for questions. Operator. Please go ahead.

Operator
19:53 - 20:09

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the pound key on your telephone keypad. The next question comes from Clemens Jäger from Stifel. Please go ahead.

Clemens Jäger
20:10 - 20:37

Hi. Thanks for the presentation and thanks for taking my question. I have one question regarding HEEALING1. So you ended up randomizing 523 patients versus 501. Was it simply because patients were still in screening? When you reached the target, was that a deliberate decision, and does it have any meaningful impact on the statistics in the end?

Christer Ahlberg
20:39 - 20:56

It is a very easy question. We had patients still in screening when we reached the target. And of course, from an ethical point of view, you want to give all patients the possibility to be enrolled. So it was nothing more than that.

Clemens Jäger
20:57 - 21:13

But that makes sense. And maybe just a second on HEEALING2. So you have started preparing for the trial. How much of the work can be done before the HEEALING1 readout? I guess the question is, how quickly after the results could you start the trial enrolling patients?

Christer Ahlberg
21:14 - 23:11

Well, of course, what we could do and what we are doing now is that we are prepared. Of course, we are preparing the protocol for the studies. We are. We are working with the picking the right CRO. So we have the requests out there. And then, of course, we also have a dialogue with the authorities. So we make sure that we have everything in place to act as fast as possible. So you can do it as seamlessly as possible. So that is what we are working on now. And the more we can do now, the faster it will go after the results of the HEEALING1 study. And also one advantage that we have now, as you have seen, is that we have executed this HEEALING1 study. We achieved a very fast recruitment time of nine months. I would say more than 500 patients. So we have a very good collaboration with both the CRO in this case, but also we have picked the right sites. So we know the high-delivery sites here and who the high performers are. And that is of course good for the feasibility of selecting the sites also in the next study, which makes it, maybe hopefully, faster. And that is our ambition, to have a flying start with higher recruitment in the early stage of the study. But otherwise, it normally takes a significant amount of time before you are up and running with the sites and recruitment. That is also the answer to your first question, that when you are up and running and have many sites very active, they recruit a lot of patients towards the end of the studies. So we want to have this recruitment pace as early as possible also for the HEEALING2 study.

Clemens Jäger
23:13 - 23:16

Okay. Thank you very much. And that is all for me.

Operator
23:20 - 23:25

The next question comes from Arvid Nicotra from ABG Sundal Collier. Please go ahead.

Arvid Nicotra
23:27 - 24:14

Good morning and thanks for taking my questions. So the first question is on HEEALING1. Now that enrollment is complete, how much visibility do you have on the available patient population, including discontinuations, protocol deviations, and disease severity splits on central review. And I guess in summary, has all of this been broadly in line with your assumptions when you powered the study? And then my second question is on HEEALING2. How much of the protocol is now effectively complete? And aside from selecting a single dose and enrolling patients both in the United States and in Europe, are there any significant changes in the study design versus HEEALING1? Those are my questions. Thanks.

Christer Ahlberg
24:14 - 26:51

Okay. Yeah. The first question is, of course, a little bit early to say yet. Now, of course, the study is still blinded. We have no insight. Insight on results or anything like that. As you know. So that is totally blind. And we will not know anything about that before we have the results. Yes, in Q4, but also, when it comes to other things, everything looks good so far. We should say that we have not closed the database yet. The study is still ongoing. So we don't have all data yet when it comes to the groups, discontinuations, and things like that; we will have the last treated patient, as I mentioned, in a couple of weeks here. But nevertheless, it looks like everything is going according to plan based on what we can see now and what I can say at this time. So that is the first question. Next question is, you asked regarding the differences between HEEALING1 and HEEALING2. And more or less, I would say, and I think it's important for everyone to understand the outcome of this study is definitely the value inflection point. The outcome of this study is what we foresee and what will also happen in the HEEALING2 study, because the protocols will look very similar to each other. Of course, it might be that we fine-tune something based on the results that we get, but overall, we do not expect to have any other outcome in the HEEALING2 study versus the HEEALING1 study. From an analyst's point of view, I would say the HEEALING1 study is the most important value inflection point. And also, of course, what we will do, hopefully, in the HEEALING1 study, we have two doses of linaprazan glurate for patients in the HEEALING1 study. Two. Our ambition is to go with only one, so that might be the biggest difference. Otherwise, the endpoints will look similar regarding what we are measuring. So definitely we do not expect to see any differences here. Does that answer your question? Did that answer your question? Okay. But let's move on to other questions. Are there other questions from the audience?

Operator
26:52 - 26:57

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad.

Christer Ahlberg
27:01 - 33:06

Okay. I think we have also some written questions which I can cover. There is a question regarding the cost of HEEALING1, specifically if all the costs have been taken now so that the remaining cash can be used for the preparation of HEEALING2. Two. Yes. Well, no, it is not. Everything is not taken yet. I mean, we have already communicated that we have cash into Q3 next year, and that includes, of course, all costs for HEEALING1, but also some of the preparation for HEEALING2; so that is already communicated and everything goes according to plan. And also, thoughts regarding a Nasdaq listing. I assume that means in the US, and of course, this is something that you always have in mind. I mean, especially depending on if you are going to commercialize it yourself in the US, then of course, that could be a solution, but there are no decisions or anything on that yet. So that's much too early for us to say anything about. Now we have another question regarding whether the results of HEEALING1 will have an impact on the design or scope of HEEALING2. Also, it's actually the same question as I just raised. And I would say, of course, it could be fine-tuned, but overall, it is more or less the same design. With the exception that we would like to reduce the number of dosing arms for linaprazan glurate to only one dosing arm. And then we had another question regarding Vonoprazan. If they cannot just deliver twice or three times daily to overcome the 24-hour gap of acid control. Well, it is not that easy. I have to say. Firstly, what we could say is that we have better acid control once daily compared to what Vonoprazan has. So we have the best acid control overall. What we also see, though, is that if they try to split their dose into two times per day, they don't gain anything. What we have seen in their own studies means that there is no reason to split the dose for them. And this once-daily dose is what they have used in the clinical trials and what they have used in the registration as we have now and what they are approved for; we see that when we split the dose, our approach differs because if we have 100mg once daily. If we split that dose into 50 milligrams twice daily, we are actually outperforming the other PCAB in terms of acid control even when compared to their once-daily dosing. And if we split the dose, we also gain quite a lot during the acute phase. What we do gain is of course that we have a smoother acid control over the 24 hours. We also make sure that we push all the patients above pH 4 for 24 hours, not only the easy to treat patients, but we also push up the difficult to treat patients and the most severe patients that really suffer from this disease. We actually have a chance to help them as well. And that is unique. That is, we have not seen anyone that can actually help these patients with this product, and actually, the severe patients are the patient group that definitely has an unmet medical need. And this is not only a patient that suffers and complains about some mild heartburn once in a while after a round of drinks the day before. These are patients that really suffer from this. They cannot carry out their day-to-day business. They cannot. The quality of life is very low. They cannot sleep during nighttime. They also have a risk of progressing into cancer if they are not healed. So this is a patient that really suffers from the acidic content in the stomach going up into the esophagus and really damaging the mucosa there. This is not to be compared with the mild heartburn that some might think this disease is about; this is a really tough disease, having a huge impact on quality of life and actually risking the patient's long-term health, with a risk of progressing into cancer, so this patient population is the one we want to help with this drug. And we have a chance actually, once and for all, to help these patients in a way that no one has done before. Okay. Are there any other questions following today's meeting? Otherwise, I will stop there. And thank you for your time. I am really looking forward to coming back to you during Q4 with the results of our Phase III trial. So let's stay in touch. Thank you very much for today's meeting.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…